China Viread patent move part of wider access push?
This article was originally published in Scrip
Executive Summary
A decision by China's State Intellectual Property Office (SIPO) to revoke one of the local patents for Gilead Sciences' HIV and hepatitis B drug Viread (tenofovir disoproxil fumarate (TDF)) appears to be part of a broader push by domestic manufacturers and authorities to widen access to affordable important medicines.